Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Circle stock falls after House GOP fails to advance crypto bills (Investing.com) +++ CIRCLE Aktie +3,06%

CARDIOL Aktie

 >CARDIOL Aktienkurs 
1.102 EUR    -3.0%    (Tradegate)
Ask: 1.122 EUR / 890 Stück
Bid: 1.094 EUR / 915 Stück
Tagesumsatz: 8900 Stück
Realtime Kurs von 8 bis 22 Uhr!
CARDIOL Aktie über LYNX handeln
>CARDIOL Performance
1 Woche: -11,3%
1 Monat: -9,8%
3 Monate: +36,9%
6 Monate: -5,3%
1 Jahr: -42,3%
laufendes Jahr: -7,9%
>CARDIOL Aktie
Name:  CARDIOL THERAPEUTICS CL.A
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA14161Y2006 / A2PA9E
Symbol/ Ticker:  CT9 (Frankfurt)
Kürzel:  FRA:CT9, ETR:CT9, CT9:GR
Index:  -
Webseite:  https://www.cardiolrx.com..
Marktkapitalisierung:  103.75 Mio. EUR
Umsatz:  -
EBITDA:  -34.8 Mio. EUR
Gewinn je Aktie:  -0.26 EUR
Schulden:  0.13 Mio. EUR
Liquide Mittel:  20.16 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 9.61 / -
Gewinnm./ Eigenkapitalr.:  - / -190.11%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  CARDIOL
Letzte Datenerhebung:  15.07.25
>CARDIOL Eigentümer
Aktien: 82.65 Mio. St.
f.h. Aktien: 79.6 Mio. St.
Insider Eigner: 4.35%
Instit. Eigner: 10.17%
Leerverk. Aktien: -
>CARDIOL Peer Group

 
29.05.25 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ......
27.05.25 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ......
29.04.25 - 13:48
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developin......
22.04.25 - 15:15
 Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
 
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors....
16.04.25 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis (Newsfile)
 
Designed to assess the impact of CardiolRx on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-o......
01.04.25 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Year-End 2024 Update on Operations (Newsfile)
 
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis; results support advancing to th......
03.03.25 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing......
20.02.25 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, f (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on develo......
04.02.25 - 16:12
 Cardiol Therapeutics to present at Oppenheimer Healthcare Conference (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
04.02.25 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the res......
03.02.25 - 11:30
 Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol (Zacks)
 
Corcept, Amneal, Dyne, Nektar and Cardiol have been highlighted in this Industry Outlook article....
18.11.24 - 20:26
 Cardiol Therapeutics präsentiert klinische Ergebnisse der Phase-II-Pilotstudie MAvERIC zu rezidivierender Perikarditis bei den Scientific Sessions 2024 der American Heart Association (IRW Press)
 
-          Eine deutliche und rasche Reduktion sowohl der Perikarditis-bedingten Schmerzen als auch der Entzündungen wurde während der 26-wöchigen Studie aufrechterhalten-          Anzahl der......
18.11.24 - 17:43
 Cardiol Therapeutics Inc.: Cardiol Therapeutics′ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 (Newsfile)
 
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support ......
22.10.24 - 16:50
 Cardiol Therapeutics will CardiolRx™ in eine Studie der späten Phase an Patienten mit rezidivierender Perikarditis überführen (IRW Press)
 
 Die Studie MAVERIC-2 wird die Auswirkungen von CardiolRx'„¢ nach dem Absetzen einer Therapie mit Interleukin-1-Blockern (Rilonacept oder Anakinra) beurteilen und wird voraussichtlich zeitgleich......
22.10.24 - 12:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics to Advance CardiolRx into a Late-Stage Trial in Patients with Recurrent Pericarditis (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the res......
11.10.24 - 14:55
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option (Newsfile)
 
Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the re......
10.10.24 - 15:25
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares (Newsfile)
 
Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the re......
09.10.24 - 14:06
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares (Newsfile)
 
Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the res......
08.10.24 - 22:12
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the rese......
24.09.24 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx for Acute Myocarditis (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the r......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Was unter den Hammer gekommen ist, braucht keinen Amboss mehr. - Dr. Fritz P. Rinnhofer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!